On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the ...
A conserved signaling axis linking Drosophila adipose tissue to nephrocyte function reveals how obesity can drive kidney dysfunction and points to new opportunities for therapeutic intervention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback